

Serial No.: To Be Assigned
Group Art Unit No.: Unknown

Sub B2
2 (Amended) A method of according to claim 1, wherein said measuring step comprises measuring the concentration of soluble E-cadherin in a sample of the patient's blood serum.

3 (Amended) A method according to claim 1 wherein said measuring step comprises measuring the concentration of soluble E-cadherin in a sample of the patient's urine.

R1 cont
4 (Amended) A method according to claim 1 or 2, wherein said measuring step comprises measuring the concentration of soluble E-cadherin in a sample of the patient's blood serum and urine.

6 (Amended) A method according to claim 5, wherein said identifying step comprises identifying the concentration of soluble E-cadherin in a sample of the patient's blood serum.

R2
7 (Amended) A method according to claim 5, wherein said identifying step comprises identifying the concentration of soluble E-cadherin in a sample of the patient's urine.

8 (Amended) A method according to claim 5, wherein said identifying step comprises identifying the levels of soluble E-cadherin in a sample of the patient's blood serum and urine.

10 (Amended) A method according to claim 9, wherein said monitoring step comprises monitoring the concentration of soluble E-cadherin in a sample of the patient's urine.

R3
11 (Amended) A method according to claim 9, wherein said monitoring step comprises monitoring the concentration of soluble E-cadherin in a sample of the patient's blood serum.

Serial No.: To Be Assigned
Group Art Unit No.: Unknown

12. (Amended) A method according to claim 9, wherein said monitoring step comprises monitoring the concentration of soluble E-cadherin in samples of the patient's urine and blood serum with time.

14. (Amended) A product according to claim 13, wherein said means to report the concentration of soluble E-cadherin comprises and anti-soluble E-cadherin antibody.

15. (Amended) A method according to claim 1 wherein the correlation graph correlates FEV1 (as a percentage of the predicted value) with soluble E-cadherin concentration.

16. (Newly Added) A method according to claim 2 wherein the correlation graph correlates FEV1 (as a percentage of the predicted value) with soluble E-cadherin concentration.

17. (Newly Added) A method according to claim 3 wherein the correlation graph correlates FEV1 (as a percentage of the predicted value) with soluble E-cadherin concentration.

18. (Newly Added) A method according to claim 4 wherein the correlation graph correlates FEV1 (as a percentage of the predicted value) with soluble E-cadherin concentration.

19. (Newly Added) A method according to claim 5 wherein the correlation graph correlates FEV1 (as a percentage of the predicted value) with soluble E-cadherin concentration.

20. (Newly Added) A method according to claim 6 wherein the correlation graph correlates FEV1 (as a percentage of the predicted value) with soluble E-cadherin concentration.

Serial No.: To Be Assigned
Group Art Unit No.: Unknown

- Sub B2
21. (Newly Added) A method according to claim 7 wherein the correlation graph correlates FEV1 (as a percentage of the predicted value) with soluble E-cadherin concentration.
22. (Newly Added) A method according to claim 8 wherein the correlation graph correlates FEV1 (as a percentage of the predicted value) with soluble E-cadherin concentration.
23. (Newly Added) A method according to claim 9 wherein the correlation graph correlates FEV1 (as a percentage of the predicted value) with soluble E-cadherin concentration.
24. (Newly Added) A method according to claim 10 wherein the correlation graph correlates FEV1 (as a percentage of the predicted value) with soluble E-cadherin concentration.
25. (Newly Added) A method according to claim 11 wherein the correlation graph correlates FEV1 (as a percentage of the predicted value) with soluble E-cadherin concentration.
26. (Newly Added) A method according to claim 12 wherein the correlation graph correlates FEV1 (as a percentage of the predicted value) with soluble E-cadherin concentration.
- cont